Moderna's Covid-19 vaccine meets primary efficacy endpoint in Phase III trial [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
The vaccine demonstrated non-inferior efficacy against Covid-19 compared to Spikevax (mRNA-1273). Notably, the trial observed higher efficacy in adults aged 18 years and above, with a consistent trend reported in those aged 65 years and older. The observer-blind, randomised, active-controlled study involved approximately 11,400 participants aged 12 and above. Participants were administered either a 10µg dose of mRNA-1283 or a 50µg dose of Spikevax. In March this year, the company reported positive interim immunogenicity data from the vaccine trial. The latest efficacy data align with the immunogenicity results, indicating that mRNA-1283 elicits stronger neutralising antibody responses against both the Omicron BA.4/5 variant and the original SARS-CoV-2 strain. In terms of safety, mRNA-1283 was found to have a profile similar to that of Spikevax, with the most common side effects being pain at the injection site, headache, fatigue, and myalgia. The vaccine is also a compo
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- COVID summer wave grows, especially in West, with new variant LB.1 on the rise [CBS News]CBS News
- Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine propaganda [Yahoo! Finance]Yahoo! Finance
- Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine propaganda [Los Angeles Times (CA)]Los Angeles Times
- How (And Why) Bird Flu Is About To Enter The "Mass Testing" Phase [zero hedge]zero hedge
- Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 6/21/24 - Form 4
- 6/18/24 - Form 144
- 6/18/24 - Form 4
- MRNA's page on the SEC website